BGPT: Author Review: Yakov Kipnis

Fuel Your Discoveries

Quick Explanation Copied

Quick appraisal — Yakov Kipnis (author)

Works: 27; citations ≈1.0–1.3k; h-index ≈15–16. Appears as recurring co-author on high-impact protein-design papers (Nature, Science, Nat. Chem. Biol., JACS) showing strength in computational protein design and enzyme engineering, often as mid-author in lab-led consortia — i.e., technical contributor in strong teams rather than lone PI leading multiple independent landmark studies.

Representative high-impact contributions include the 2023 Nature luciferase design (large multi-author team) and a 2012 Nature Chemical Biology enzyme redesign paper demonstrating sustained relevance in enzyme design across >10 years of work.

Sources: OpenAlex author metrics and representative papers below.

Long Explanation

Author Review — Yakov Kipnis

Visual summary — metrics & role

Interpretation: modest publication count with above-average citation reach (≈1.0–1.3k), indicating high-impact co-authorships rather than a large independent corpus.

Evidence-focused appraisal (visual first)

Interpretation: episodic publication activity with large citation spikes in 2012, 2023, and 2024 consistent with high-impact collaborative works (e.g., 2012 enzyme redesign and 2023 luciferase design).

Representative high-impact papers (selected)

Critical synthesis — strengths and limits

Strengths: Repeated co-authorship on experimental + computational enzyme/protein-design studies published in top-tier journals (Nature, Science, Nat Commun, JACS, NChemBio) indicates strong technical competence in computational protein design and participation in high-quality experimental validation pipelines; citation spikes correspond to community-valued contributions ().

Limitations / red flags: Low independent paper count and frequent middle-author placement suggest role as a technical collaborator rather than an independent group leader publishing many first-/last-author papers; author affiliation metadata is sparse in the provided data (no consistent primary institution listed), which complicates assessing leadership, lab resources, and independent reproducibility work. Some highly-cited collaborative papers are recent; long-term reproducibility and follow-up outside the originating teams remain to be seen ().

Potential biases & blindspots considered: collaborative, high-impact labs can obscure individual contribution; publication bias toward positive engineering outcomes in protein design; possible sponsor/industry ties in translational works (not shown explicitly here); many papers are method-development + demonstration — risk of overgeneralization if results are not reproduced in independent labs.

Where evidence would change this assessment

Discovery of multiple first/last-author experimental studies by Kipnis showing independent reproducible pipelines would raise independent leadership score.
Independent replication (outside original teams) of designed enzymes' activities at scale would strengthen claims of translational robustness.
Conversely, failed reproductions or evidence of data-selection would lower confidence.

Direct citations (representative) — full inline sources

Feedback:

Updated: February 15, 2026